Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

Two antibody-drug conjugates are among 10 programs that the company expects to fuel its growth, the company said.

Merck (NYSE:MRK) says it now sees up to $70 billion in new revenue opportunities by the mid-2030s, as it works to offset the ...

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Merck announced on Monday that it has significantly raised its long-term growth outlook, projecting up to $70 billion in revenue from new growth drivers by the mid-2030s. The updated forecast ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

With that as the backdrop, here's a rundown of three dividend stocks to buy with plans to only hold them for the next 10 ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...